Modern opportunities of treatment of tuberculosis with multi-drug resistant mycobacteria

J.-P. Zellweger

Abstract


Multidrug-resistant tuberculosis (MDR-TB) is a major threat to tuberculosis control in many parts of the world. The current options for managing this form of the disease are an optimal use of existing drugs, use of re-purposed or new drugs and some non-antibiotic therapeutic options. The prevention of the creation and transmission of drug-resistant strains will be crucial for the global management of tuberculosis in the future.

Keywords


tuberculosis, drug-resistant tuberculosis, MDR-TB

References


World Health Organization. The global plan to stop TB 2011-2015. Geneva: World Health Organization; 2011.

World Health Organization. Towards tuberculosis elimination: an action framework for low-incidence countries: WHO; 2014. Report No.: WHO/HTM/TB/2014.13.

Wolinsky E RA, Steenken W Jr. Drug-resistant tubercle bacilli in patients under treatment with streptomycin. Am Rev Tuberc 1948;58:335-43.

van der Werf MJ, Langendam MW, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012;39:1511-9.

Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 2015;19:1276-89.

Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013;208:1464-73.

Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 2015;21:1223-7.

World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization; 2016. Report No.: WHO/HTM/TB/2016.13.

Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Medicine 2012;9:e1001300.

Royce S, Falzon D, van Weezenbeek C, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis 2013;17:511-3.

Yablonskii PK, Vizel AA, Galkin VB, Shulgina MV. Tuberculosis in Russia. Its history and its status today. Am J Respir Crit Care Med 2015;191:372-6.

World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Geneva: world health organization; 2016. Report No.: WHO/HTM/TB/2016.04.

Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016;48:516-25.

Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.

Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2009;13:1320-30.

Dominguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016;20:24-42.

Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 2013:CD004795.

Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 2016.

Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447-54.

Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [Review article]. Int J Tuberc Lung Dis 2013;17:1001-7.

Jaganath D, Lamichhane G, Shah M. Carbapenems against Mycobacterium tuberculosis: a review of the evidence. Int J Tuberc Lung Dis 2016;20:1436-47.

Gunther G, Gomez GB, Lange C, Rupert S, van Leth F, on behalf of the T. Availability, price and affordability of anti-tuberculosis drugs in Europe: A TBNET survey. Eur Respir J 2014.

Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92.

Aung KJ, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014;18:1180-7.

Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014;18:1188-94.

Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Eur Respir J 2016.

van Altena R, Akkerman OW, Alffenaar JC, et al. Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. Eur Respir J 2016;48:1800-2.

World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, 2013.

World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, 2014.

Bloemberg GV, Keller PM, Stucki D, et al. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med 2015;373:1986-8.

Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016;48:935-8.

Lachatre M, Rioux C, Le Du D, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 2016;16:294.

Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016;20:177-86.

Gopal P, Dick T. The new tuberculosis drug Perchlozone(R) shows cross-resistance with thiacetazone. Int J Antimicrob Agents 2015;45:430-3.

Яблонский П.К., Виноградова Т.И., Левашев Ю.Н. и [др.] Терапевтический архив. 2016; Т.8 (33); 111-115.

Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010;182:1080-5.

Abate G, Hoft DF. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther 2016;5:37-45.

Hofman S, Segers MM, Ghimire S, et al. Emerging drugs and alternative possibilities in the treatment of tuberculosis. Expert Opin Emerg Drugs 2016;21:103-16.

Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8.

Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. ClinInfectDis 2005;41:201-8.

Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm 2015;478:517-29.

Das S, Tucker I, Stewart P. Inhaled dry powder formulations for treating tuberculosis. Curr Drug Deliv 2015;12:26-39.

Levin A, Sklyuev S, Felker I, Tceymach E, Krasnov D. Endobronchial valve treatment of destructive multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016;20:1539-45.

Dara M, Sotgiu G, Zaleskis R, Migliori GB. Untreatable tuberculosis: is surgery the answer? Eur Respir J 2015;45:577-82.

World Health Organization regional office for Europe. The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB: WHO regional office for Europe; 2014.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 J.-P. Zellweger


Яндекс.Метрика Рейтинг@Mail.ru